5α-androstane-3α,17p-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: Implication of androgen-independent prostate cancer progression

Journal of Cellular Biochemistry

Volumn 104, Issue 5, 2008, Pages 1612-1624

  Yang, Qing ^a   Titus, Mark A ^b   Fung, Kar Ming ^a,c   Lin, Hsueh Kung ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen; Androgen receptor; Cell growth; Prostate cancer

Indexed keywords

3ALPHA DIOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTERONE DERIVATIVE; BETA CATENIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANDROSTANEDIOL; AR PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; APOPTOSIS; BIOLOGICAL MODEL; CYTOPLASM; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; TUMOR GENE;

ANDROSTANE-3,17-DIOL; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOPLASM; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 50249118153     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21731     Document Type: Article

References (49)

1. Agapova OA, Malone PE, Hernandez MR. 2006. A neuro-active steroid 5α-androstane-3α, 17β-diol regulates androgen receptor level in astrocytes. J Neurochem 98: 355-363.
2. Aguilera O, Munoz A, Esteller M, Fraga MF. 2007. Epigenetic alterations of the Wnt/β-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 7:13-21.
3. Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM. 2006. Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: A potential therapeutic target for androgen dependent disease. Mol Endocrinol 20:444-458.
4. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. 2004. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64:8867-8875.
5. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. 2003. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 17:590-603.
6. Chen S, Song CS, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B, Roy AK. 1998. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 12:1558-1566.
7. Chinni SR, Sarkar FH. 2002. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8:1228-1236.
8. Coffey DS, Isaacs JT. 1981. Control of prostate growth. Urology 17:17-24.
9. Daneshgari F, Crawford ED. 1993. Endocrine therapy of advanced carcinoma of the prostate. Cancer 71:1089-1097.
10. Ding VD, Moller DE, Feeney WP, Didolkar V, Nakhla AM, Rhodes L, Rosner W, Smith RG. 1998. Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway. Endocrinology 139: 213-218.
11. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. 2000. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7:997-1007.
12. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM, Lin HK. 2006. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13:169-180.
13. Gatson JW, Kaur P, Singh M. 2006. Dihydrotestosterone differentially modulates the mitogen-activated protein kinase and the phosphoinositide 3-kinase/Akt pathways through the nuclear and novel membrane androgen receptor in C6 cells. Endocrinology 147:2028-2034.
14. Jacobi GH, Moore RJ, Wilson JD. 1978. Studies on the mechanism of 3α-androstanediol-induced growth of the dog prostate. Endocrinology 102:1748-1755.
15. Kang HY, Cho CL, Huang KL, Wang JC, Hu YC, Lin HK, Chang C, Huang KE. 2004. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res 19: 1181-1190.
16. Leihy MW, Shaw G, Wilson JD, Renfree MB. 2001. Virilization of the urogenital sinus of the tammar wallaby is not unique to 5α-androstane- 3α, 17α-diol. Mol Cell Endocrinol 181:111-115.
17. Leihy MW, Shaw G, Wilson JD, Renfree MB. 2004. Penile development is initiated in the tammar wallaby pouch young during the period when 5α-androstane-3α, 17α-diol is secreted by the testes. Endocrinology 145:3346-3352.
18. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM. 1997. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: Demonstration of bifuntional 3α/17β-HSD activity and cellular distribution. Mol Endocrinol 11:1971-1984.
19. Lin J, Adam RM, Santiestevan E, Freeman MR. 1999. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59:2891-2897.
20. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. 2003. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902-50907.
21. Mahendroo MS, Cala KM, Russell DW. 1996. 5α-reduced androgens play a key role in murine parturition. Mol Endocrinol 10:380-392.
22. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. 2004. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64: 765-771.
23. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. 2001. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805.
24. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y, Sasano H. 2005. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12:101-107.
25. Nishiyama T, Hashimoto Y, Takahashi K. 2004. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10:7121-7126.
26. Nunlist EH, Dozmorov I, Tang Y, Cowan R, Centola M, Lin HK. 2004. Partitioning of 5α-dihydrotestosterone and 5α-androstane-3α, 17β-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation. J Steroid Biochem Mol Biol 91:157-170.
27. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K. 2000. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77.
28. Penning TM, Bauman DR, Jin Y, Rizner TL. 2007. Identification of the molecular switch that regulates access of 5α-DHT to the androgen receptor. Mol Cell Endocrinol 265-266:77-82.
29. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. 2003. Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922-2932.
30. Schultz FM, Wilson JD. 1974. Virilization of the Wolffian duct in the rat fetus by various androgens. Endocrinology 94:979-986.
31. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. 2000. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 132:566-577.
32. Sharifi N, Gulley JL, Dahut WL. 2005. Androgen deprivation therapy for prostate cancer. JAMA 294:238-244.
33. Sharma M, Chuang WW, Sun Z. 2002. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941.
34. Shaw G, Renfree MB, Leihy MW, Shackleton CH, Roitman E, Wilson JD. 2000. Prostate formation in a marsupial is mediated by the testicular androgen 5α-androstane-3α, 17α-diol. Proc Natl Acad Sci USA 97:12256-12259.
35. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. 2004. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 22:2546-2553.
36. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825.
37. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. 2003. Activation of phosphatidylinositol 3-Kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src. J Biol Chem 278:42992-43000.
38. Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, KantoffPW, Oh WK. 2004. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 15:974-978.
39. Terry S, Yang X, Chen MW, Vacherot P, Buttyan R. 2006. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 99:402-410.
40. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. 2005. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657.
41. Voigt KD, Bartsch W. 1986. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25:749-757.
42. Walsh PC, Wilson JD. 1976. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 57:1093-1097.
43. Wright ME, Tsai MJ, Aebersold R. 2003. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17:1726-1737.
44. Wu C, Huang J. 2007. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282:3571-3583.
45. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. 2006. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 103:7789-7794.
46. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT, Chang C. 2005a. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280:33558-33565.
47. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. 2005b. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5:8.
48. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. 1993. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53:1304-1311.
49. Zimmerman RA, Dozmorov I, Nunlist EH, Tang Y, Li X, Cowan R, Centola M, Frank MB, Culkin DJ, Lin HK. 2004. 5α-Androstane-3α, 17β-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation. Prostate Cancer Prostatic Dis 7:364-374.